FDA OKs Merck tablet to reduce ragweed allergies

April 17, 2014 by The Associated Press

U.S. regulators have again approved a Merck & Co. tablet for gradually reducing seasonal allergies, this time for ragweed pollen.

Ragwitek tablets dissolve quickly under the tongue. Patients are to take one daily, from three months before ragweed season begins until it ends, for a few years. The Food and Drug Administration approved it for patients aged 18 through 65.

Whitehouse Station, N.J.-based Merck's tablet for spring grass allergies, Grastek, was approved Monday for patients aged 5 to 65.

Both offer an alternative to medicines that just temporarily relieve symptoms or years of uncomfortable allergy shots.

The shots and tablets work by gradually tamping down immune response to allergy-triggering substances and reducing sneezing, runny noses and itchy, watery eyes.

Ragwitek and Grastek should be available in pharmacies by April 30.

Explore further: FDA OKs Merck tablet to reduce grass allergies

Related Stories

FDA OKs Merck tablet to reduce grass allergies

April 15, 2014
Merck & Co. says the Food and Drug Administration has approved its new tablet for grass allergies, Grastek, for patients five to 65 years old.

Canada approves Merck grass allergy immunotherapy

February 3, 2014
Merck & Co. says it's won its first approval for its new immunotherapy tablet for grass allergies, from regulators in Canada.

Merck says FDA reviewing its ragweed allergy therapy

May 8, 2013
Drugmaker Merck & Co. says the Food and Drug Administration is reviewing its second application to sell a new type of allergy treatment meant to gradually reduce allergic reactions over time, rather than just relieving sneezing, ...

Merck: FDA reviewing tablet to eliminate allergy

March 27, 2013
Drugmaker Merck & Co. says federal regulators are reviewing its application to sell a new type of treatment for grass pollen allergy that gradually reduces allergy symptoms over time, rather than just temporarily relieving ...

US approves novel remedy for hayfever, pollen allergies (Update)

April 2, 2014
US regulators on Wednesday approved a French-made remedy for alleviating symptoms of hayfever and certain allergies to grass pollen.

FDA panel considers first pill for ragweed allergy

January 28, 2014
(HealthDay)—There may be good news coming in the form of a pill for the millions of Americans who suffer from ragweed allergy.

Recommended for you

FDA bans use of opioid-containing cough meds by kids

January 12, 2018
(HealthDay)—Trying to put a dent in the ongoing opioid addiction crisis, the U.S. Food and Drug Administration on Thursday slapped strict new restrictions on the use of opioid-containing cold and cough products by kids.

Taking ibuprofen for long periods found to alter human testicular physiology

January 9, 2018
A team of researchers from Denmark and France has found that taking regular doses of the pain reliever ibuprofen over a long period of time can lead to a disorder in men called compensated hypogonadism. In their paper published ...

Nearly one-third of Canadians have used opioids: study

January 9, 2018
Nearly one in three Canadians (29 percent) have used "some form of opioids" in the past five years, according to data released Tuesday as widespread fentanyl overdoses continue to kill.

Growing opioid epidemic forcing more children into foster care

January 8, 2018
The opioid epidemic has become so severe it's considered a national public health emergency. Addiction to prescription painkillers, such as oxycodone and morphine, has contributed to a dramatic rise in overdose deaths and ...

Price tag on gene therapy for rare form of blindness: $850K

January 3, 2018
A first-of-its kind genetic treatment for blindness will cost $850,000 per patient, making it one of the most expensive medicines in the world and raising questions about the affordability of a coming wave of similar gene-targeting ...

Restasis: Why US consumers paid billions for drug deemed ineffective in other countries

January 2, 2018
Why are Americans, both as patients and taxpayers, paying billions of dollars for a drug whose efficacy is so questionable that it's not approved in the European Union, Australia or New Zealand? Restasis, a blockbuster drug ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.